Skip to main content
EirGenix logo

EirGenix — Investor Relations & Filings

Ticker · 6589 ISIN · TW0006589005 TW Manufacturing
Open in API
Filings indexed 41 across all filing types
Latest filing 2026-04-28 AGM Information
Country TW Taiwan
Listing TW 6589

About EirGenix

http://www.eirgenix.com

EirGenix, Inc. operates under a dual-engine business model, integrating Contract Development and Manufacturing Organization (CDMO) services with the development of proprietary biologics. The company provides comprehensive solutions spanning cell line development, process optimization, analytical testing, and cGMP-compliant manufacturing for both mammalian and microbial cultures. Its technical infrastructure includes large-scale production capabilities with multiple 2,000-liter single-use bioreactors and advanced continuous manufacturing platforms. EirGenix’s internal pipeline focuses on high-quality biosimilars, notably HER2-targeted therapies for breast cancer, including Trastuzumab biosimilar assets. Additionally, the company produces specialty products such as the CRM197 carrier protein and diagnostic tools. By leveraging integrated development and manufacturing expertise, EirGenix delivers cost-effective biopharmaceutical solutions to support global healthcare needs.

Recent filings

Filing Released Lang Actions
115年年報及股東會資料 — 2026_6589_20260529F02.pdf
AGM Information Classification · 100% confidence The document is titled as a shareholder meeting manual for the Annual General Meeting (AGM) of the company 台康生技 for the year 民國115 (2026). It includes detailed agenda items typical of an AGM such as announcements, chairman's speech, reports, approvals, discussions, and adjournment. The document contains attachments including the 114年度營業報告書 (114 Annual Business Report), audit committee report, remuneration policy, financial statements, and other governance documents. The content is comprehensive and includes the full agenda and supporting materials for the AGM, not just an announcement or summary. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM. The document length (15,000 characters) and detailed content confirm it is the meeting materials themselves, not just an announcement or proxy statement. Therefore, the correct classification is AGM Information (AGM-R).
2026-04-28 Chinese
115年年報及股東會資料 — 2026_6589_20260529F13.pdf
AGM Information Classification · 95% confidence The document is the “115年股東常會議事手冊” (shareholders’ annual general meeting handbook) containing the AGM agenda, proposals, attachments (114年度營業報告書, 審計委員會報告書, 董事酬金政策, 財務報表, 公司章程, etc.) and supporting materials for the Annual General Meeting. This matches the definition of AGM Information (AGM-R) – materials shared during an AGM.
2026-04-28 Chinese
115年年報及股東會資料 — 2026_6589_20260529FE1.pdf
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a formal notice for the 2026 Annual Shareholders’ Meeting, detailing agenda items, proposed resolutions, instructions for attendance and proxy submission, and includes the proxy form – characteristics of materials sent to shareholders to solicit votes. This aligns with the Proxy Solicitation & Information Statement category (PSI), rather than reporting periods, earnings releases, or AGM presentations.
2026-04-28 English
115年年報及股東會資料 — 2026_6589_20260529F01.pdf
Proxy Solicitation & Information Statement Classification · 86% confidence The document is a formal notice and proxy statement for the company’s annual general meeting (115th shareholders’ meeting). It contains the meeting agenda, proxy form, trustee rules, and detailed proposals for shareholder approval (e.g., issuance of restricted stock, private placement). This is not the AGM presentation itself, nor a report of results, but a solicitation/information statement sent to shareholders to vote. Therefore, it matches the Proxy Solicitation & Information Statement category (PSI).
2026-04-28 Chinese
本公司受邀參加玉山證券舉辦之法人說明會
Regulatory Filings Classification · 66% confidence The document is a mandatory public disclosure to the Taiwanese market’s public information observatory. It announces the date, time, venue, and purpose of an upcoming institutional investor briefing (“法人說明會”), but does not include the presentation slides or detailed financial data itself. This is not the full investor presentation (IP) nor an earnings release, nor a proxy or regulatory statement about management or share issues, but a regulatory announcement of an event. Thus it falls into the general "Regulatory Filings" fallback category (RNS).
2026-04-20 Chinese
115年04月法人說明會簡報
Investor Presentation Classification · 85% confidence The document is from a public disclosure site listing details of a “法人說明會” (institutional investor briefing) – date, time, location, and links to the presentation materials. This corresponds to an Investor Presentation (IP) rather than an earnings release or regulatory filing.
2026-04-20 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.